RE: ASCO2 Jun 2023 16:18
Yes,but is he presenting about ava6000??π€
Presenter: William D. Tap, MD
Session: Poster Session, Phase I study of the mutant IDH1 inhibitor ivosidenib: Long-term safety and clinical activity in patients with conventional chondrosarcoma
Date/Time: Saturday, June 3, 1:15 p.m. (CDT)
Presenter: William D. Tap, MD
Session: Poster Session, Safety, pharmacokinetics (PK), and clinical activity of bezuclastinib + sunitinib in previously-treated gastrointestinal stromal tumor (GIST): Results from part 1 of the phase 3 Peak study
Date/Time: Saturday, June 3, 1:15 p.m.